CN105664146A - 增强免疫力的药物及其制备方法 - Google Patents
增强免疫力的药物及其制备方法 Download PDFInfo
- Publication number
- CN105664146A CN105664146A CN201610029842.9A CN201610029842A CN105664146A CN 105664146 A CN105664146 A CN 105664146A CN 201610029842 A CN201610029842 A CN 201610029842A CN 105664146 A CN105664146 A CN 105664146A
- Authority
- CN
- China
- Prior art keywords
- enhancing immunity
- medicine
- examples
- effective
- purity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 52
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims description 8
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 claims abstract description 5
- 102000007625 Hirudins Human genes 0.000 claims abstract description 5
- 108010007267 Hirudins Proteins 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims abstract description 5
- 229940006607 hirudin Drugs 0.000 claims abstract description 5
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims abstract description 5
- 235000013793 astaxanthin Nutrition 0.000 claims description 14
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 13
- 239000001168 astaxanthin Substances 0.000 claims description 13
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 13
- 229940022405 astaxanthin Drugs 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 229930014669 anthocyanidin Natural products 0.000 claims description 9
- 150000001452 anthocyanidin derivatives Chemical class 0.000 claims description 9
- 235000008758 anthocyanidins Nutrition 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 229930182490 saponin Natural products 0.000 claims description 5
- 150000007949 saponins Chemical class 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 241000572565 Alpinia oxyphylla Species 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 claims description 3
- 239000010017 yuan zhi Substances 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 abstract description 31
- 210000004369 blood Anatomy 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 18
- 235000020661 alpha-linolenic acid Nutrition 0.000 abstract description 16
- 229960004488 linolenic acid Drugs 0.000 abstract description 16
- 230000006870 function Effects 0.000 abstract description 11
- 230000004438 eyesight Effects 0.000 abstract description 10
- 235000019197 fats Nutrition 0.000 abstract description 8
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 7
- 230000035764 nutrition Effects 0.000 abstract description 6
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 230000032683 aging Effects 0.000 abstract description 5
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 2
- 230000018109 developmental process Effects 0.000 abstract description 2
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 241001127637 Plantago Species 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 210000004720 cerebrum Anatomy 0.000 abstract 1
- 229930193974 gastrodin Natural products 0.000 abstract 1
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 14
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 13
- 210000004204 blood vessel Anatomy 0.000 description 12
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 12
- 208000007536 Thrombosis Diseases 0.000 description 11
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 11
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 11
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 11
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000237903 Hirudo Species 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000004626 essential fatty acids Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 241001464837 Viridiplantae Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000009978 visual deterioration Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 241000229143 Hippophae Species 0.000 description 1
- 241000237678 Hirudinidae Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 240000007930 Oxalis acetosella Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 241000293001 Oxytropis besseyi Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000961970 Plantago depressa Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 241000964941 Whitmania Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- UZFLPKAIBPNNCA-BQYQJAHWSA-N alpha-ionone Chemical group CC(=O)\C=C\C1C(C)=CCCC1(C)C UZFLPKAIBPNNCA-BQYQJAHWSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- -1 phylloxanthin Chemical compound 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000010152 pollination Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
服用1个月 | 服用2个月 | 服用4个月 | |
实施例1 | 5例有效 | 6例显效,3例有效 | 1例治愈,4例显效,4例有效,1例无效 |
实施例2 | 5例有效 | 7例显效,3例有效 | 5例治愈,5例显效 |
实施例3 | 5例有效 | 6例显效,4例有效 | 5例治愈,5例显效 |
实施例4 | 7例有效 | 8例显效,2例有效 | 7例治愈,3例显效 |
实施例5 | 7例有效 | 7例显效,3例有效 | 7例治愈,3例显效 |
实施例6 | 6例有效 | 7例显效,3例有效 | 6例治愈,4例显效 |
实施例7 | 5例有效 | 7例显效,3例有效 | 6例治愈,4例显效 |
实施例8 | 8例有效 | 9例显效,1例有效 | 8例治愈,2例显效 |
实施例9 | 9例有效 | 9例显效,1例有效 | 8例治愈,2例显效 |
实施例10 | 10例有效 | 1治愈例,9例显效 | 10例治愈 |
实施例11 | 10例有效 | 2治愈例,8例显效 | 10例治愈 |
实施例12 | 10例有效 | 1治愈例,9例显效 | 10例治愈 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610029842.9A CN105664146A (zh) | 2016-01-16 | 2016-01-16 | 增强免疫力的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610029842.9A CN105664146A (zh) | 2016-01-16 | 2016-01-16 | 增强免疫力的药物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105664146A true CN105664146A (zh) | 2016-06-15 |
Family
ID=56301181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610029842.9A Pending CN105664146A (zh) | 2016-01-16 | 2016-01-16 | 增强免疫力的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105664146A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106474463A (zh) * | 2016-12-06 | 2017-03-08 | 衡阳茂晨农业开发有限公司 | 防治美国青蛙胃肠炎的中药组合物及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628845A (zh) * | 2003-12-17 | 2005-06-22 | 昆明紫健生物技术有限公司 | 一种具有生物活性的复方药物制剂 |
CN1732916A (zh) * | 2004-08-09 | 2006-02-15 | 李川明 | 含原花青素和其它功能成分的复方医疗保健制剂 |
CN102188438A (zh) * | 2010-03-05 | 2011-09-21 | 昆明制药集团股份有限公司 | 乙酰天麻素在制备防治血管性痴呆和阿尔茨海默症药物中的应用 |
CN102228241A (zh) * | 2011-05-27 | 2011-11-02 | 赵锐 | 健脑益智增强记忆保健食品及其制备方法 |
CN103768352A (zh) * | 2014-02-17 | 2014-05-07 | 杜志政 | 一种天然平糖颗粒及其制备方法 |
CN104107424A (zh) * | 2014-07-31 | 2014-10-22 | 杜志政 | 治疗心脑血管疾病的养气溶栓药物组合物及其制备方法 |
CN105106809A (zh) * | 2015-09-21 | 2015-12-02 | 刘兴全 | 治疗卵巢癌的制剂及制备方法 |
CN105104936A (zh) * | 2015-09-11 | 2015-12-02 | 颍上县天好食品有限公司 | 一种鱼子紫薯淀粉 |
-
2016
- 2016-01-16 CN CN201610029842.9A patent/CN105664146A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628845A (zh) * | 2003-12-17 | 2005-06-22 | 昆明紫健生物技术有限公司 | 一种具有生物活性的复方药物制剂 |
CN1732916A (zh) * | 2004-08-09 | 2006-02-15 | 李川明 | 含原花青素和其它功能成分的复方医疗保健制剂 |
CN102188438A (zh) * | 2010-03-05 | 2011-09-21 | 昆明制药集团股份有限公司 | 乙酰天麻素在制备防治血管性痴呆和阿尔茨海默症药物中的应用 |
CN102228241A (zh) * | 2011-05-27 | 2011-11-02 | 赵锐 | 健脑益智增强记忆保健食品及其制备方法 |
CN103768352A (zh) * | 2014-02-17 | 2014-05-07 | 杜志政 | 一种天然平糖颗粒及其制备方法 |
CN104107424A (zh) * | 2014-07-31 | 2014-10-22 | 杜志政 | 治疗心脑血管疾病的养气溶栓药物组合物及其制备方法 |
CN105104936A (zh) * | 2015-09-11 | 2015-12-02 | 颍上县天好食品有限公司 | 一种鱼子紫薯淀粉 |
CN105106809A (zh) * | 2015-09-21 | 2015-12-02 | 刘兴全 | 治疗卵巢癌的制剂及制备方法 |
Non-Patent Citations (1)
Title |
---|
谢东浩,武谦虎主编: "《常用治疗肿瘤中药》", 31 December 2015, 中国医药科技出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106474463A (zh) * | 2016-12-06 | 2017-03-08 | 衡阳茂晨农业开发有限公司 | 防治美国青蛙胃肠炎的中药组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5864252B2 (ja) | 炮製を活用した薬用植物抽出物及びこれを含有する皮膚外用剤組成物 | |
CN107397208B (zh) | 以鱼鳔胶为主成分的功能食品及其用途 | |
CN104351578A (zh) | 一种用于治疗鸡劳伤的配合饲料及其制备方法 | |
CN101869287B (zh) | 芪蜂软胶囊及其制备方法 | |
CN102940153A (zh) | 一种改善肉质、蛋质的家禽饲料 | |
CN105454576A (zh) | 茉莉花八宝茶及其制备方法 | |
CN105010669A (zh) | 一种清润保健茉莉花茶及其生产方法 | |
CN103330175B (zh) | 一种天然植物组合物调味品及其制备方法 | |
CN107853517A (zh) | 一种提神抗疲劳的中药饮料及其制备方法 | |
CN108310298A (zh) | 一种具有缓解眼疲劳、防治近视的中药组合物及制备方法 | |
CN102604750A (zh) | 一种林下草本基植物生物质洗涤剂的制备方法 | |
CN105482965B (zh) | 一种养生保健酒及其制备方法 | |
CN105639497A (zh) | 一种海参火腿肠的配方及其加工工艺 | |
CN105435197A (zh) | 一种治疗桥本氏病的药物组合物及其制备方法 | |
CN105664146A (zh) | 增强免疫力的药物及其制备方法 | |
CN101496604A (zh) | 一种具有降血脂功能的营养食品及其制备方法 | |
KR20160147424A (ko) | 와송 추출물이 포함된 효소조성물 | |
CN104544084A (zh) | 一种用于糖尿病患者的保健食品 | |
CN105747134A (zh) | 一种芭蕉芋风味鲳鱼卷的制作方法 | |
KR20090021410A (ko) | 피로할 때 마시는 대추 침출 차 조성물과 그 제조방법 | |
CN1861166A (zh) | 一种治疗高胰岛素型多囊卵巢综合症的药物组合物及其制备方法 | |
CN110771764A (zh) | 一种茉莉花香醋饮料的制备方法 | |
CN109645477A (zh) | 一种调养五脏增强免疫作用的药食同源食品及其制备方法 | |
KR101285458B1 (ko) | 항암작용을 하는 건강보조식품 및 그 제조방법 | |
CN106434176A (zh) | 具有降三高功能的保健酒及其生产方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160630 Address after: 423029 Chenzhou city of Hunan province Suxian District Liang Tian Zhen Liao Jia Wan fourteen group Applicant after: Hunan Tianzheng pharmaceutical Limited by Share Ltd Address before: 100162 Beijing, Xihongmen, Jinhua, garden area, building 3, unit 3, unit, 501 Applicant before: Du Zhizheng Applicant before: Zhang Min |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170124 Address after: 100162 Beijing, Xihongmen, Jinhua, garden area, building 3, unit 3, unit, 501 Applicant after: Du Zhizheng Applicant after: Zhang Min Address before: 423029 Chenzhou city of Hunan province Suxian District Liang Tian Zhen Liao Jia Wan fourteen group Applicant before: Hunan Tianzheng pharmaceutical Limited by Share Ltd |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20180129 Address after: 518000 Guangdong city of Shenzhen province Nanshan District Xili Xili Street Kan Yang Industrial Zone No. 5 5 501 floor Applicant after: Shenzhen Chi Tong Pharmaceutical Technology Co. Ltd. Address before: Unit 3, building No. 3, gardener District, Jinhua, Xihongmen 501 Applicant before: Du Zhizheng Applicant before: Zhang Min |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160615 |
|
RJ01 | Rejection of invention patent application after publication |